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To investigate interactions of dietary LC-PUFA, a dose-response study with a range of 24 
docosahexaenoic acid (DHA; 22:6n-3) levels (1g kg-1, 5 g kg-1, 10 g kg-1, 15 g kg-1 and 20 g kg-1) 25 
was performed with post-smolts (111 ± 2.6 g; mean ± S.D.) over a nine-week feeding period. 26 
Additional diets included 10 g kg-1 DHA in combination with 10 g kg-1 of either eicosapentaenoic 27 
acid (EPA; 20:5n-3) or arachidonic acid (ARA; 20:4n-6), and a diet containing 5g kg-1 each of 28 
DHA and EPA. Liver, brain, head kidney and gill were collected at the conclusion of the trial and 29 
lipid and fatty acid compositions determined as well as expression of genes of LC-PUFA 30 
biosynthesis. Total lipid content and class composition were largely unaffected by changes in 31 
dietary LC-PUFA. However, phospholipid (PL) fatty acid compositions generally reflected that of 32 
the diet, although the response varied between tissues. Liver most strongly reflected diet, followed 33 
by head kidney. In both tissues increasing dietary DHA led to significantly increased DHA in PL 34 
and inclusion of EPA or ARA led to higher levels of these fatty acids. Brain showed the most 35 
conserved composition and gene expression profile, with increased dietary LC-PUFA resulting in 36 
only minor changes in PL fatty acids. Dietary LC-PUFA significantly affected the expression of Δ6 37 
and Δ5 desaturases, Elovl 2, 4 and 5, and SREBPs although this varied between tissues with 38 
greatest effects observed in liver followed by head kidney, similar to PL fatty acid compositions. 39 
 40 
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1. Introduction 47 
It is now widely appreciated that fish, particularly oily species such as Atlantic salmon (Salmo 48 
salar), herring (Clupea harengus) and mackerel (Scomber scombrus), represent a rich and almost 49 
unique source of n-3 long-chain (≥C20) polyunsaturated fatty acids (LC-PUFA) in the human diet 50 
(Bell et al., 2001; Tocher, 2009; Monroig et al., 2010). The beneficial health effects of these fatty 51 
acids are well established through the roles they play in cardiovascular disease (Calder, 2004), 52 
inflammatory and autoimmune diseases (Simopoulos, 2002) and neurological disorders (Dyall & 53 
Michael-Titus, 2008). At the same time, there are concerns surrounding the accumulation of 54 
contaminants in fish and the perceived health risks these may pose to the human consumer, 55 
although scientific evidence is lacking and risks have yet to be defined or quantified (Bell & 56 
Waagbø, 2008; Tocher, 2009). However, the most urgent issue is that worldwide demand for 57 
aquatic food products continues to grow beyond the sustainable limits of global capture fisheries 58 
(Sargent & Tacon, 1999). This has resulted in significant growth of the aquaculture sector in recent 59 
decades and, coupled with changes in public attitude towards the sustainability of the industry, the 60 
continued production of high-quality, n-3 LC-PUFA-rich fish faces a number of challenges 61 
(Subasinghe et al., 2009). 62 
Atlantic salmon represents one of the most economically important species for aquaculture 63 
worldwide but, as a carnivorous species, it also presents somewhat of a paradox. The aquafeeds 64 
used to rear Atlantic salmon have traditionally relied upon high proportions of fish oils derived 65 
from small, pelagic marine fish on the basis that they provide an excellent source of n-3 LC-PUFA 66 
(Sargent & Tacon, 1999; Bendiksen et al., 2011). However, the majority of world stocks for these 67 
forage fish are considered to be either fully or over-exploited (FAO, 2012), and the limited supply 68 
of fish oil is only exacerbated by competition for inclusion in human nutritional supplements and 69 
agricultural feeds (Bell et al. 2001; Naylor et al. 2009). Consequently, much of the research in 70 
recent years has focussed on sustainable alternatives to fish oils, principally vegetable oils 71 
(reviewed by Nasopoulou & Zabetakis, 2012). Numerous feeding trials have revealed that growth, 72 
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feed conversion and survival of Atlantic salmon are largely unaffected when fish oil is partially 73 
replaced by vegetable oil (Tortensen et al,. 2000; Bell et al., 2001; Rosenlund et al., 2001; 74 
Bransden et al., 2003). However, vegetable oils are notable for their lack of LC-PUFA, indicating 75 
that high replacement of fish oils cannot be accomplished without compromising product quality 76 
through reduced flesh n-3 LC-PUFA content (Bell et al., 2003; Menoyo et al., 2005; Tocher, 2010). 77 
Therefore, the reputation of farmed Atlantic salmon as a health promoting food seems reliant upon 78 
a better understanding of the functional requirements and metabolism of LC-PUFA. 79 
All vertebrates including fish require three key fatty acids for normal growth and 80 
development: docosahexaenoic acid (DHA; 22:6n-3), eicosapentaenoic acid (EPA; 20:5n-3) and 81 
arachidonic acid (ARA; 20:4n-6) (Sargent et al., 1997; Bell, 1998; Sargent et al., 1999). These 82 
biologically active fatty acids play important roles in cell membrane structure and function 83 
(Sargent et al. 2002), the regulation of reproduction (Bell & Sargent, 2003) and the modulation of 84 
immune responses (Waagbø, 1994). Salmonids can synthesise these LC-PUFA de novo from their 85 
C18 precursors α-linolenic acid (LNA; 18:3n-3) and linoleic acid (LOA; 18:2n-6), though their 86 
capacity for this is limited (Castell et al., 1972; Bell et al., 1993; Tocher et al., 2000). The enzymes 87 
involved in the bioconversion of both n-3 and n-6 PUFA to LC-PUFA are the Δ-6 and Δ-5 fatty 88 
acyl desaturases (FADS2D6 and FADS2D5 respectively) and two fatty acyl elongases (ELOVL2 89 
and ELOVL5). The Δ6 desaturation of both C18 and C24 PUFA is likely required for the 90 
biosynthesis of DHA in salmon, although there are three functional FADS2D6 in Atlantic salmon 91 
that may indicate differential regulation of these desaturation steps (Monroig et al., 2010). 92 
Similarly, two functional ELOVL5 (a and b) have been identified in salmon (Morais et al., 2009). 93 
Functional studies suggest that ELOVL5 is mainly involved in the elongation of C18→C20 PUFA, 94 
with residual C20→C22 activity, whereas ELOVL2 elongates C20→C22 but not C18→C20 (Morais et 95 
al., 2009). The activity of the LC-PUFA biosynthesis pathway relies on the presence of substrates 96 
but also transcription factors (TF) such as sterol regulatory element binding protein (SREBP) 1 97 
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and 2 or liver X receptor (LXR), which may be involved in gene regulation (Carmona-Antoñanzas 98 
et al., 2014).  99 
To understand performance characteristics at the level of the organism in greater detail, it is 100 
necessary to evaluate the different roles that LC-PUFA play within individual tissues. Thus, liver is 101 
considered an important site for LC-PUFA synthesis and lipid metabolism in Atlantic salmon 102 
(Monroig et al., 2010). Neural tissues like brain and retina are characteristically rich in DHA 103 
(Tocher & Harvie, 1988; Bell & Tocher, 1989), and thus, DHA-deficient diets lead to impaired 104 
visual performance (Bell et al., 1995). Head kidney is of interest because it forms a key component 105 
of the fish immune system (Tort et al. 2003), the functions of which are known to be influenced by 106 
dietary LC-PUFA (Waagbø, 1994; Lall, 2000). Specifically, LC-PUFA are considered essential for 107 
the production of eicosanoids such as leukotrienes, prostaglandins and thromboxanes, substances 108 
that act as key mediators between immune cell membranes and inflammatory responses in fish 109 
(Rowley et al. 1995; Martinez-Rubio et al., 2013). The gills are another tissue susceptible to 110 
dietary changes in PUFA and this is of specific interest because, on top of respiration, the gills play 111 
vital roles in osmoregulation and ion balance (Bell et al., 1992; 1996).  112 
Phospholipids (PL), major constituents of cell lipids, tend to be fairly constant in composition 113 
under normal physiological conditions, enabling functional associations to be drawn between 114 
different organs/tissues (Christie, 2003a). In addition, LC-PUFA are preferentially deposited in PL 115 
over triacylglycerol (TAG) (Sargent et al., 2002). It was hypothesised that the PL fatty acid 116 
compositions of liver, brain, head kidney and gill tissues of Atlantic salmon would respond 117 
differently to altered dietary LC-PUFA based on their individual fatty acid requirements and 118 
functional roles in lipid and fatty acid metabolism. The present study therefore aimed to examine 119 
the different tissue specificities for DHA, in addition to potential interactions with either EPA or 120 
ARA in post-smolts fed diets containing varying levels of these essential LC-PUFA. Furthermore, 121 
the study sought to evaluate the influence dietary LC-PUFA may have on total lipid contents and 122 
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compositions of the different tissues, in addition to understanding the molecular mechanisms 123 
involved in the control and regulation of LC-PUFA metabolism. 124 
 125 
1. Materials and Methods 126 
2.1. Experimental diets 127 
A single basal diet was formulated to provide protein and lipid at 460 g kg-1 and 200 g kg-1 128 
diet at a gross energy level of 22.0 MJ kg-1 (estimated digestible protein and energy of 440 g kg-1 129 
and 19.5 MJ kg-1, respectively). A total of eight experimental diets were produced by vacuum 130 
coating the dry basal extruded pellets with custom, pre-mixed oil blends as follows. To investigate 131 
the effect of DHA concentration, a series of five DHA inclusion levels (1 g kg-1, 5 g kg-1, 10 g kg-132 
1, 15 g kg-1 and 20 g kg-1, named D1, D5, D10, D15 and D20 respectively) were created using a 133 
blend of oils that included an algal DHA source derived from Crypthecodinium sp. (HuaTai 134 
BioPharm Inc., Deyang, Sichuan, China) along with a combination of clarified butterfat and olive 135 
oil as a lipid base (Table 1). To examine additional effects of EPA and ARA inclusion, three 136 
further treatments were created. Two EPA diets containing either 10 g kg-1 (D10E) or 5 g kg-1 137 
(D5E) each of EPA and DHA were formulated using anchovy oil that contained EPA and DHA in 138 
equal amounts. A single ARA treatment (D10A) was formulated using fungal-derived concentrate 139 
(HuaTai BioPharm Inc., Deyang, Sichuan, China) to include 10 g kg-1 each of ARA and DHA. For 140 
full compositional analysis of experimental diets see Table 2 and for additional information on diet 141 
manufacture refer to Glencross et al. (2014). 142 
 143 
1.2. Fish and husbandry 144 
Prior to experimental work, Atlantic salmon smolts were sourced from Howietoun hatchery 145 
(Bannockburn, Scotland) and transferred to the Marine Environmental Research Laboratory 146 
(Machrihanish, Argyll, Scotland) where they were on-grown to 110.9 ± 2.61 g (mean ± S.D.) post-147 
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smolts in two 10,000 L seawater tanks. All fish were anesthetized using benzocaine prior to 148 
handling. The fish were weighed on an electronic toploading balance to 0.5 g accuracy and 20 fish 149 
allocated to each of 24 x 500 L tanks. The experimental system comprised a flow-through, 150 
ambient water temperature, 500 L x 24-tank array. Water temperature was 14.0 ± 0.82°C (mean ± 151 
S.D.) and dissolved oxygen was at 7.8 ± 0.60 mg L-1 (mean ± S.D.) for the duration of the 9-week 152 
experiment. All eight treatments were fed in triplicate (three tanks of 20 fish each). Experimental 153 
feeds were delivered on a restricted pair-wise feeding regime to eliminate feed intake variability, 154 
and feed rations were increased incrementally over the duration of the study. Further details of 155 
feeding regime are provided elsewhere (Glencross et al., 2014). 156 
 157 
1.3. Sample collection and management 158 
At the end of the feeding trial, a total of six fish (two per tank) from each treatment were 159 
randomly sampled and euthanized by benzocaine overdose. Samples of liver, brain, gill and head 160 
kidney tissue were collected from each fish and immediately frozen in liquid nitrogen prior to 161 
storage at -70 °C. Approximately 100 mg of each individual tissue was sampled for total RNA 162 
extraction, whereas paired samples from each tank were pooled to form individual replicates by 163 
treatment and tissue type for total lipid extraction. 164 
 165 
1.4. Total lipid extraction 166 
Lipid was extracted from tissue samples using a modified method of Folch et al. (1957). 167 
Briefly, liver and gill samples were homogenized in 16 ml of chloroform/methanol (2:1, v/v) using 168 
an Ultra-Turrax tissue disrupter (Fisher Scientific, Loughborough, UK), while brain and head 169 
kidney samples were homogenized using a glass-barrel homogenizer in the same volume of 170 
solvent. Non-lipid impurities were isolated by washing with 4 ml of 0.88% aqueous KCl (w/v). 171 
The upper aqueous layer was removed by aspiration and the lower solvent layer containing the 172 
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lipid extract dried under oxygen-free nitrogen. Total lipid content was determined gravimetrically 173 
after overnight desiccation in vacuo.  174 
 175 
1.5. Lipid class composition 176 
Lipid classes were separated by double-development, high-performance thin-layer 177 
chromatography (HPTLC) using 10 x 10 cm plates (VWR, Lutterworth, UK) according to 178 
Henderson & Tocher (1992). Total lipid samples (1-2 µg) were applied as 3 mm origins and the 179 
plates developed in methyl acetate/isopropanol/chloroform/methanol/0.25% aqueous KCl 180 
(25:25:25:10:9, by vol.) to 5.2 cm. Excess solvent was evaporated via air drying and vacuum 181 
desiccation and plates developed to 9.5 cm using a solvent mixture containing iso-hexane/diethyl 182 
ether/acetic acid (80:20:1, by vol.) before termination and drying as above. Lipid classes were 183 
visualized by spraying with 3% (w/v) aqueous cupric acetate containing 8% (v/v) phosphoric acid 184 
and charring plates at 160 °C for 20 min. Lipid classes were quantified by densitometry using a 185 
CAMAG-3 TLC scanner (version Firmware 1.14.16; CAMAG, Muttenz, Switzerland) with 186 
winCATS software (Planar Chromatography Manager, version 1.2.3). 187 
 188 
1.6. Phospholipid fatty acid composition 189 
Phospholipids were isolated using thin-layer chromatography (TLC) by loading 2 mg of total 190 
lipid onto 2.5 cm origins on 20 x 20 cm TLC plates (VWR, Lutterworth, UK) and running in a 191 
solvent mixture comprising isohexane/diethyl ether/acetic acid (80:20:1, by vol.). Plates were 192 
sprayed with 1% (w/v) 2’,7’-dichlorofluorescein in 97% (v/v) methanol containing 0.05% (w/v) 193 
BHT and visualized under UV light (UVGL-58 Minerallight® Lamp, Ultraviolet Prod. Inc., Calif., 194 
USA). Total polar lipids were scraped into test tubes and fatty acid methyl esters (FAME) were 195 
prepared by acid-catalyzed transmethylation according to the method of Christie (2003b). FAME 196 
were separated and quantified by gas-liquid chromatography using a Fisons GC-8160 (Thermo 197 
Scientific, Milan, Italy) equipped with a 30 m × 0.32 mm i.d. × 0.25 μm ZB -wax column 198 
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(Phenomenex, Cheshire, UK), on-column injector and a flame ionization detector. Hydrogen was 199 
used as the carrier gas in constant flow mode at 2.5 ml min-1, with an initial oven thermal gradient 200 
from 50 °C to 150 °C at 40 °C min−1 to a final temperature of 230 °C at 2 °C min−1. Data were 201 
collected and processed using Chromcard for Windows (version 2.01; Thermoquest Italia S.p.A., 202 
Milan, Italy). Individual FAME were identified by comparison to known standards and published 203 
data (Ackman, 1980; Tocher & Harvie, 1988). Selected FAME were confirmed by gas 204 
chromatography-mass spectrometry (GC-MS) using a gas chromatograph (GC8000) coupled to a 205 
MD800 mass spectrometer (ThermoFisher Scientific, Hemel Hempstead, UK). 206 
 207 
1.7. RNA extraction and quantitative real time PCR (qPCR) 208 
Five of the eight experimental treatments were chosen for the gene expression study. These 209 
diets were chosen to represent a low DHA level (D1), an “optimum” level according to previous 210 
studies (D10; Glencross et al., 2014), and the three combinations of LC-PUFA (D10A, D10E and 211 
D5E). Liver, brain, gill and head kidney samples from six individual fish per treatment (n = 2 fish 212 
per tank) were homogenized in TriReagent® (Sigma-Aldrich, Dorset, UK) RNA extraction buffer 213 
following the manufacturer’s instructions. Quantity and quality of isolated total RNA were 214 
determined by spectrophotometry with an ND-1000 Nanodrop (Labtech Int., East Sussex, UK) and 215 
electrophoresis using 500 ng of total RNA in a 1% agarose gel. cDNA was synthesized using 2 μg 216 
of total RNA and random primers in 20 μl reactions and the High capacity reverse transcription kit 217 
without RNase inhibiter according to the manufacturer’s protocol (Applied Biosystems, 218 
Warrington, UK). The resulting cDNA was diluted 20-fold with milliQ water.  219 
For qPCR, primers for fatty acyl desaturases and elongases, and TF involved in their 220 
regulation, were used (see Table 3). The efficiency of the primers for each gene was previously 221 
evaluated to ensure that it was close to 100%. In addition, two reference genes, cofilin-2 and 222 
elongation factor-1α were quantified. qPCR was performed using a Biometra TOptical 223 
Thermocycler (Analytik Jena, Goettingen, Germany) in 96-well plates in duplicate 20 μl reaction 224 
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volumes containing 10 μl of SYBR Green RT-PCR Master Mix (Applied Biosystems, Paisley, 225 
UK), 1 μl of the primer corresponding to the analyzed gene (10 pmol), 3 μl of molecular biology 226 
grade water and 5 μl of cDNA, with the exception of the reference genes, which were determined 227 
using 2 μl of cDNA. In addition amplifications were carried out with a systematic negative control 228 
(NTC-non template control) containing no cDNA. Standard amplification parameters contained an 229 
initial activation step at 95 ˚C for 15 min, followed by 35 cycles: 15 s at 95 ˚C, 30 s at the 230 
annealing Tm and 30 s at 72 ˚C . A calibrator sample was included within each plate in order to 231 
compare the gene expression among the different tissues/plates.  232 
 233 
1.8. Statistical Analysis 234 
All data are means ± S.D. (n = 3) unless otherwise specified. Percentage data for total lipid 235 
content, lipid class composition and polar lipid fatty acid composition were all subjected to arcsin 236 
square-root transformation prior to analyses. Effects of DHA inclusion level (diets D1-D20) were 237 
examined with regression analysis. Additionally, effects of EPA and ARA inclusion were 238 
examined against equivalent levels of DHA. Specifically, the 10 g kg-1 diets D10 and D5E were 239 
examined by one-way analysis of variance (ANOVA), while the 20 g kg-1 diets D20, D10A and 240 
D10E were examined by one-way ANOVA followed by a Tukey-Kramer HSD multiple 241 
comparison of means. All statistical analyses were performed using Minitab (version 16.1.0; 242 
Minitab Inc., State college, PA). 243 
Gene expression results were analyzed using the relative expression software tool (REST 244 
2008; http://www.gene-quantification.info/), which employs a pairwise fixed reallocation 245 
randomization test (10,000 randomizations) with efficiency correction (Pfaffl et al., 2002) to 246 
determine the statistical significance of expression ratios (gene expression fold changes) between 247 
two treatments. In addition, a supervised hierarchical clustering was applied employing the relative 248 
gene expression ratio for each gene based on the PCR efficiency and Ct of sample compared to the 249 
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control, according to Pfaffl’s mathematical model (Pfaffl, 2001). Tree View software (Page, 1996) 250 
was used to generate visual representations of the classification.  251 
 252 
2. Results 253 
3.1. Total lipid content 254 
In general lipid content was fairly constant across all eight dietary treatments (Tables 4-7). 255 
Brain tissue had the highest mean lipid content (7.7%), followed by liver (4.8%) and head kidney 256 
(4.2%), while gill tissue contained on average just 1.7% lipid (Tables 4-7). Increasing inclusion of 257 
DHA in the diet (D1-D20) had no significant effect on lipid content in any of the tissues examined. 258 
The lipid content of head kidney from fish fed diet D20 was lower than that of fish fed diet D10E 259 
(Table 5), and brain lipid content was higher in fish fed diet D5E compared with those fed diet 260 
D10 (Table 7). Other than these differences, the mixed LC-PUFA diets had no significant effects 261 
on tissue lipid contents. 262 
 263 
2.2. Lipid class composition 264 
In general the dietary treatments had little effect on the lipid class compositions of liver, brain, 265 
head kidney and gill. The proportions of phospahtidylcholine (PC) and cholesterol were slightly, 266 
but significantly, increased and the proportion of phosphatidylinositol (PI) decreased, in liver with 267 
increasing dietary DHA (data not shown). Increasing dietary DHA had no significant effect on the 268 
lipid class composition of head kidney, gill or brain. The level of TAG in brain was highly variable 269 
between fish fed the different diets although only significant in fish fed diet D10E, which had 270 
higher TAG than fish fed diets D20 or D10A (data not shown). Other than this, the diets with 271 





2.3. Fatty acid compositions of liver and head kidney phospholipids 275 
The predominant fatty acids in liver PL were DHA, 18:1n-9 and 16:0, though overall fatty 276 
acid composition was readily influenced by that of the diet (Tables 2, 4 & 5). Relative 277 
concentrations of DHA, EPA and ARA in liver PL were always considerably higher than those of 278 
the diet, while total saturated fatty acids (SFA) and total monounsaturated fatty acids (MUFA) 279 
were consistently lower than those of the diet. Increased inclusion of DHA in the diet resulted in a 280 
highly significant increase (10.4 %) in the concentration of DHA in the liver (P<0.001) and 281 
correspondingly increased total n-3 PUFA and LC-PUFA (Table 4). The relative contents of EPA 282 
and docosapentaenoic acid (DPA; 22:5n-3) in the liver tended to decrease with increasing DHA, 283 
while levels of ARA and 22:4n-6 were largely unaffected. Total SFA content of liver PL remained 284 
fairly stable, but MUFA content decreased significantly across diets D1-D20, reflecting the dietary 285 
levels of these fatty acid groups. The concentration of 22:5n-6 in liver PL increased significantly in 286 
fish fed diets D1 through to D20 reflecting the increasing level of this fatty acid in these diets 287 
(Tables 2 & 4). 288 
Inclusion of other LC-PUFA (EPA and ARA) in the diet also influenced the fatty acid 289 
composition of liver PL (Table 5). Inclusion of EPA (diets D5E & D10E) resulted in DHA levels 290 
similar to those found in liver PL from fish fed equivalent diets containing DHA alone (D10 and 291 
D20) (Tables 2 & 5). EPA inclusion also tended to increase the levels of both EPA and DPA found 292 
in liver PL, with the higher inclusion of EPA resulting in highly significant increases (P<0.001) in 293 
these fatty acids relative to diets D20 and D10A (Table 5). Furthermore, diets D5E and D10E 294 
resulted in the lowest levels of ARA in liver PL. Inclusion of ARA (D10A) resulted in significantly 295 
higher levels of ARA and 22:4n-6 in liver PL compared with DHA alone (D20) (Table 5). Diet 296 
D10A also resulted in the lowest level of EPA in liver PL out of all the diets. Inclusion of EPA or 297 
ARA also clearly altered the EPA/ARA ratio in their favour, but there were no significant effects of 298 
EPA or ARA inclusion on the relative amount of SFA or MUFA. 299 
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The fatty acid composition of head kidney PL differed from that of liver in that it contained 300 
slightly more SFA and slightly less PUFA (Tables 4 & 5). Additionally, head kidney contained a 301 
small percentage of dimethyl acetals (DMA; 2.6 % total fatty acids), derived from plasmalogen 302 
PL, not observed in the liver. However, the effects of increased dietary DHA were broadly the 303 
same as those described for liver PL, although the mean increase in relative DHA content in head 304 
kidney was not as defined as in liver (5.6 % vs. 10.4 % total fatty acids) (Table 4). Effects of EPA 305 
or ARA inclusion on the fatty acid composition in head kidney PL were also very similar to those 306 
observed in liver PL (Table 5). 307 
2.4. Fatty acid compositions of brain and gill phospholipids 308 
The fatty acid composition of brain PL showed a number of general differences to that of liver 309 
PL. Brain PL contained a notable proportion (> 7% total fatty acids) of DMA (Tables 6 & 7). In 310 
addition, the relative content of EPA was higher, and that of ARA lower in brain PL compared to 311 
liver PL.  Furthermore, the relative MUFA content of brain PL (due to higher 24:1n-9, not shown) 312 
was noticeably higher than that of the liver (39.6 vs. 23.3 % total fatty acids) (Tables 6 & 7). 313 
Increasing DHA inclusion resulted in only a small, but significant, increase (1.7 %) in the relative 314 
DHA content of brain PL (Table 6). Relative SFA contents increased slightly and relative MUFA 315 
contents decreased in fish fed diets D1 through D20, reflecting dietary compositions (Tables 2 & 316 
6). EPA and DPA both declined in brain PL in fish fed diets D1 through D20, although the effects 317 
were subtle in comparison to the liver (Table 6). Diets D1-D20 had no effect on the relative 318 
amounts of ARA and 22:4n-6 in brain PL, whereas 22:5n-6 increased in line with dietary levels 319 
(Table 6). Effects of EPA and ARA inclusion on the fatty acid composition of brain PL also 320 
followed the same overall patterns as seen in the liver, but the magnitude of these effects was 321 
generally much lower (Table 7). It was notable that the EPA/ARA ratio was always positive, even 322 
when fish were fed diet D10A with increased ARA. The fatty acid composition of gill PL 323 
contained slightly higher percentages of ARA and 22:4n-6 and slightly lower percentages of EPA 324 
and DPA than liver PL, and total PUFA content was consistently lower (Tables 6 & 7). Relative 325 
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SFA and MUFA contents were slightly higher than that of liver PL. Like brain, increasing DHA 326 
inclusion did not have the same clear effect on relative DHA content in gill PL as observed in liver, 327 
and the relationship was non-significant (P = 0.057) (Table 6). Effects of EPA or ARA inclusion 328 
were similar to those for liver but less pronounced (Table 7). 329 
2.5. Tissue expression profile of lipid metabolism genes 330 
Differing dietary LC-PUFA contents affected the expression of the studied genes, although the 331 
effects varied between the tissues. Therefore, brain showed the more stable expression pattern 332 
whereas, in contrast, liver showed the highest number of altered genes, followed by head kidney 333 
(Fig. 1). Increased dietary DHA content from 1 to 10 g kg-1 significantly reduced the mRNA 334 
abundance of desaturases fads2d6b, fads2d6c and fads2d5, as well as elovl2 and elovl4 in liver 335 
(Fig. 2), but no dietary effect was observed in brain (Fig. 3). Reduced expression of both fads2d6b 336 
and fads2d5 was also observed in head kidney and gill, respectively, although statistically non-337 
significant (Figs. 4 & 5). Generally, fish fed diet D10A displayed the lowest expression of all the 338 
fatty acyl desaturases and elongases genes studied in head kidney and liver, though this tendency 339 
was not observed in brain and gill. Both elovl5a and 5b showed variable expression in all tissues 340 
with the only statistically significant difference found in brain where fish fed diet D10A showed 341 
highest expression of elovl5b.  342 
Regarding TF, lxr gene expression did not differ among fish fed any of the diets in any of the 343 
tissues. In contrast, srebp1 expression was up-regulated in liver (Fig. 2) and gill (Fig. 5) of fish fed 344 
diet D1, head kidney of fish fed D10E (Fig. 3), and brain of fish fed D10A (Fig. 4). Gene 345 
expression of srebp2 was only significantly regulated only in liver, with lower expression in fish 346 
fed D10A (Fig. 2). 347 
 348 
3. Discussion 349 
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Increasing dietary DHA and additional EPA and ARA to Atlantic salmon had clear effects on 350 
PL fatty acid compositions of all tissues although the precise nature and magnitude of the effects 351 
varied markedly between the tissues. Liver, brain, head kidney and gill were chosen in the present 352 
study based on the different roles they play in LC-PUFA metabolism and vice versa, the varied role 353 
LC-PUFA play in the functions of the tissues. In this context, the liver was of interest because of its 354 
important roles in LC-PUFA biosynthesis and overall body lipid homeostasis in Atlantic salmon 355 
(Tocher et al., 2003; Monroig et al., 2010; Martinez-Rubio et al., 2013). In contrast, in common 356 
with other higher vertebrates, brain of fish is characteristically enriched in DHA (Tocher & Harvie, 357 
1988; Bell & Tocher, 1989) and so was of particular interest in the present study where dietary 358 
DHA was the primary variable. Head kidney in fish forms an integral component of the immune 359 
system (Tort et al,. 2003; Gjøen et al., 2007), and so was of interest because dietary lipid and PUFA 360 
content are known to influence immune function and thus health status of fish (Waagbø, 1994; Lall, 361 
2000; Martinez-Rubio et al., 2013). Finally, previous work had shown that gill phospholipid fatty 362 
acid compositions significantly alter during the smoltification process and that these changes can be 363 
influenced by diet (Bell et al., 1997; Tocher et al., 2000). 364 
The results of the present study showed that lipid content of the brain was the highest of all the 365 
tissues examined (~ 7.7% wet weight), which was comparable with the value of 7.1% reported for 366 
Atlantic salmon by Stoknes et al. (2004). There was a clear trend for lipid content in brain to 367 
increase when EPA or ARA was added to the diets although this was only significant in fish fed 368 
D5E. The increased lipid content was driven by increased TAG content but the reason for this was 369 
unclear. It may be that the relative level of DHA was lower when EPA and ARA was present and so 370 
not all uptake was able to be processed for PL synthesis/turnover. Liver and head kidney lipid 371 
content did not vary significantly, perhaps because the lipid and energy content was fairly stable 372 
across all dietary treatments (Martinez-Rubio et al., 2013), while analysis of gill revealed the lowest 373 
lipid content of any of the tissues examined, on average just 1.65% wet tissue weight, which is 374 
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similar to the low gill lipid content (range 0.6 – 1.4%) found for turbot, Scophtalmus maximus 375 
(Castell et al., 1994).  376 
The fatty acid profiles of the four tissues analyzed showed different patterns likely related to 377 
their physiological functions. The fatty acid composition of liver PL largely reflected that of the 378 
diet, which is consistent with other studies on Atlantic salmon (Brodtkorb et al., 1997; Bell et al., 379 
2003; Bransden et al., 2003). The relative DHA content of liver PL was always considerably higher 380 
than that of the diet, indicating the important role of this fatty acid in cell membranes (Sargent et al., 381 
2002). In contrast, relative levels of SFA and MUFA in liver PL were noticeably lower than those 382 
of the feed, suggesting selective discrimination and/or preferential β-oxidation of these fatty acids 383 
(Henderson & Sargent, 1985; Turchini & Francis, 2009). The fatty acid composition of brain PL 384 
was much more conserved and less affected by diet than the liver, consistent with other studies 385 
examining these tissues in Atlantic salmon (Bell et al., 1990; Brodtkorb et al., 1997) and turbot 386 
(Bell et al., 1999). This implied a slower turnover of lipids and fatty acids in the brain, although the 387 
relatively short duration of the experiment may have limited the ability to detect greater differences 388 
between dietary groups.  389 
Ruyter et al. (2000) showed that increasing inclusion of DHA and EPA in the diets of Atlantic 390 
salmon fry led to increased percentages of these fatty acids in liver PL. Similarly, in the present 391 
study, increasing dietary DHA through diets D1-D20 led to a highly significant increase in the 392 
percentage of DHA in liver PL. However, this contrasted with the results of Bell et al. (1989) who 393 
found no significant differences in the relative amount of DHA in liver PL when Atlantic salmon 394 
post-smolts were fed diets containing either fish oil or a combination of corn oil and lard, despite 395 
the former diet containing three times more DHA. Regression analysis showed that increasing 396 
dietary DHA led to only a small increase in the relative DHA content of brain PL, probably 397 
reflecting the fact that brain PL fatty acid composition is much more tightly controlled rather than 398 
any particular control on DHA uptake. Indeed, work on juvenile Atlantic salmon by Brodtkorb et al. 399 
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(1997) found no effects of increasing dietary DHA content on the fatty acid composition or on DHA 400 
levels within individual lipid classes of the brain. However, the diets used in the previous study 401 
contained much higher levels of DHA (range 6.3 – 17.9 % total fatty acids) representing dietary 402 
contents far above any reported requirement levels compared with the present study that included 403 
levels of DHA that may be more limiting (range 0.5 – 7.6 % total fatty acids). Interestingly, the 404 
significance of the response in brain in the present study was removed when the lowest DHA 405 
treatment (D1) was excluded from analysis (P = 0.454), supporting the view that only very low 406 
DHA affected brain PL fatty acid compositions, and not dietary DHA above requirement levels.  407 
Previous studies on the replacement of fish oil with soybean oil in the diets of Atlantic salmon 408 
showed a reduction in the percentage of DHA in head kidney total lipid, consistent with the reduced 409 
DHA content of vegetable oil-based diets (Gjøen et al., 2004). Similarly, the present study showed 410 
that increasing inclusion of DHA in the diet was reflected in head kidney PL with increased 411 
percentages of DHA, though the magnitude of effect was only half that observed in liver. The head 412 
kidney contains high numbers of immune cells and so changes in dietary fatty acid composition has 413 
the potential to alter cell membrane physiology and immune function of these cells (Mourente et al., 414 
2007). In contrast, increasing dietary DHA did not significantly affect the percentage of DHA in gill 415 
PL, although variation observed between replicates in D10-fed fish may have influenced this. 416 
However, there was still no obvious trend and so the effect, if any, was subtle in comparison to the 417 
liver. Overall, this may suggest more selective uptake of DHA in gill PL, or more conserved 418 
composition, as observed in brain PL. 419 
Given that the impact of dietary DHA was most clearly observed in the liver, it is likely that 420 
liver in Atlantic salmon plays an important role in the initial selectivity for DHA, as reported in 421 
other vertebrates (Polozova & Salem, 2007). Despite very low levels of DPA in the diet, its higher 422 
content in liver PL may suggest that endogenous synthesis of DHA from LNA and/or EPA may 423 
have ocurred in at least the lower inclusion of DHA (D1). Consistent with this, fads2d6b, fadsd26c 424 
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and fads2d5 expression were higher in fish fed 1 g kg-1 of DHA denoting an upregulation of the LC-425 
PUFA biosynthesis pathway as previously described (Moya-Falcón et al., 2005; Thomassen et al., 426 
2012). The elongation of EPA to DPA appears to be very active in Atlantic salmon liver 427 
(Thomassen et al., 2012), which is in agreement with the present study, where high expression of 428 
both elovl2 and elovl5 was observed together with high levels of DPA. However, only statistical 429 
differences were found in elovl2, suggesting a greater role of this enzyme compared to elovl5 in 430 
elongation of C20 PUFA. Similarly, heterologous expression in yeast showed that salmon elovl5 431 
elongated C18 and C20 PUFA, with low activity towards C22, whereas elovl2 elongated C20 and C22 432 
PUFA with lower activity towards C18 (Morais et al., 2009). Interestingly, elovl4 expression was 433 
also upregulated in liver of fish fed 1 g kg-1 of DHA. ELOVL4 is involved in the synthesis of very 434 
long-chain PUFA (> C24) in mammals, but it was recently shown that Atlantic salmon elovl4 open 435 
reading frame (ORF) was able to elongate both EPA and ARA (15.4 % and 11.5% conversion, 436 
respectively) indicating that it was also involved in LC-PUFA biosynthesis (Carmona-Antoñanzas 437 
et al., 2011). These data are consistent with the results in the present study, where high 438 
concentrations of DPA could be due to combined activity of the different fatty acid elongases. In 439 
contrast, the highest inclusion of DHA (D20) was at the upper end of the documented requirement 440 
for LC-PUFA in salmonids (Ruyter et al., 2000) and this probably suppressed further endogenous 441 
synthesis of DHA in the liver, gill and head kidney (Bell & Sargent, 2003; Zheng et al., 2004).  442 
Dietary inclusion of EPA or ARA typically resulted in increased levels of these fatty acids in 443 
the PL of all studied tissues, reflecting the preferential incorporation of LC-PUFA into cell 444 
membranes (Sargent et al., 2002). These two fatty acids had inverse reciprocal effects on their 445 
respective levels in tissue PL such that inclusion of one reduced the relative amount of the other, 446 
highlighting their strong biological link in fatty acid metabolism (Bell et al., 1989). In addition, the 447 
tissue proportion of DHA was increased in fish fed both diets containing EPA, regardless of total 448 
LC-PUFA content, whereas inclusion of ARA appeared to have the opposite effect in that it 449 
lowered the relative amount of DHA and also EPA present in liver, head kidney and gill PL. In 450 
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contrast, DHA levels in the brain were not affected by dietary EPA or ARA denoting once again the 451 
importance of this fatty acid for neural functions. It was noteworthy that EPA did not appear to 452 
influence the activity of fatty acyl desaturases, as the EPA level in diet D1 was similar to the other 453 
diets, but fish fed diet D1 displayed an up-regulation in these enzymes, especially in liver, head 454 
kidney and gill. This may indicate a key role for DHA in the regulation of desaturase expression as 455 
has been suggested previously (Thomassen et al., 2012). However, results obtained from a previous 456 
in vitro study showed inhibition of desaturation and elongation of 18:3n-3 when EPA or DHA were 457 
added to the cell medium (Zheng et al., 2009). This earlier study was performed on an established 458 
cell line where cells reflect the fatty acid composition of the foetal bovine serum present in the 459 
medium, thus the response to LC-PUFA may vary when compared to an in vivo model (Tocher et 460 
al., 1988). 461 
Interestingly, brain PL consistently maintained a positive EPA/ARA ratio, even when fish were 462 
fed diet D10A, which contained much more ARA than EPA (5.1% vs 0.6% total fatty acids). A 463 
similar effect was seen on a whole-body mass basis in a study with Asian seabass (Lates calcarifer) 464 
when they were fed diets similar to the D10A and D10E used in the present study (Glencross et al., 465 
2011). Both EPA and ARA are well known to compete as substrates for eicosanoid synthesis in 466 
vertebrates (Bell et al., 1994; Calder, 2006). This suggests a preferential incorporation of EPA over 467 
ARA in brain PL. Inclusion of EPA and ARA in the diet was of particular relevance to the head 468 
kidney because of the key role of eicosanoids in immune/inflammatory responses (Martinez-Rubio 469 
et al., 2013). In this sense, the addition of ARA to the diet resulted in significantly higher ARA in 470 
head kidney PL, which may have increased inflammatory potential in these fish. This may have in 471 
part contributed to the lower survival of this dietary group reported previously (Glencross et al., 472 
2014). On the other hand, inclusion of EPA in the diet resulted in an increased percentage of EPA in 473 
head kidney PL, and this would presumably increase the availability of anti-inflammatory 474 
eicosanoids. Indeed, recent trials using functional feeds containing both reduced lipid content and 475 
increased EPA have been shown to reduce the intensity of inflammatory responses associated with 476 
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Atlantic salmon reovirus-induced HSMI (heart and skeletal muscle inflammatory disease) 477 
(Martinez-Rubio et al., 2012). Another trial modulating the inclusion of EPA and DHA in the diet 478 
of Asian seabass found acutely contrasting effects on a range of both clinical and sub-clinical 479 
inflammation markers (Glencross et al., 2011). Interestingly, the inclusion of EPA in the present 480 
study still only resulted in an EPA/ARA ratio of 1.1 in gill PL, reaffirming the bias toward ARA 481 
over EPA in this tissue. Extreme dietary alterations in these fatty acids might therefore compromise 482 
osmoregulatory function and overall health of the fish. 483 
Regulation of lipid metabolism is complex and controlled by several TF including SREBPs and 484 
LXR. In mammals, SREBP1 is involved in activation of genes that participate in fatty acid 485 
metabolism and de novo lipogenesis whereas SREBP2 is more selective for genes involved in 486 
cholesterol homeostasis (Horton et al., 2004). Furthermore, n-3 and n-6 fatty acids can induce 487 
transcription of lxr through DR1 elements (Tobin et al., 2002) and regulate the expression of srebp1 488 
(Joseph et al., 2002), which is a major regulator of lipogenesis in mammals (Davidson, 2006). In the 489 
present study the diet with highest LC-PUFA content (D10A; 13.5 %) was found to down-regulate 490 
the expression of srebp1 in liver, whereas fish fed diet D1, with only 1% LC-PUFA, showed the 491 
highest expression. This is in agreement with previous studies in Atlantic salmon both in vitro 492 
(Minghetti et al., 2011) and in vivo (Morais et al., 2011) where srebp1 expression was reduced by 493 
LC-PUFA supplementation, denoting a similar nutritional regulation to mammals (Davidson et al., 494 
2006; Caputo et al., 2010). Similarly, this lower expression profile was reflected in lower 495 
expression levels of some SREBP1 target genes such as fads2d6c and fads2d5. However, this 496 
pattern of expression was not observed in all tissues and so, in contrast, srebp1 expression in brain 497 
was highest in D10A-fed fish. Conversely, lxr gene expression was not affected by dietary PUFA 498 
content. The explanation to this could be that LXR is activated by a variety of sterols, including 499 
intermediates in the synthesis of cholesterol, and adequate levels of cholesterol were present in all 500 
of the diets, which could also explain why srebp2 expression was unaffected.  501 
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In summary, the present study demonstrated that manipulation of dietary LC-PUFA directly 502 
affected the fatty acid profile of tissue PL and gene expression of key metabolic tissues in post-503 
smolt Atlantic salmon. Liver displayed the greatest response to dietary DHA, accumulating this 504 
fatty acid in higher amounts than any other tissue, with increased expression of key enzymes 505 
involved in LC-PUFA synthesis in fish fed the lowest DHA diet. A qualitatively similar but 506 
quantitatively lower effect was observed in head kidney. In contrast, PL fatty acid profile and gene 507 
expression was more conserved in brain and less affected by dietary treatment, and a similar 508 
response to diet was observed in gill. The tissue variation observed most likely reflected the unique 509 
functions of each tissue. 510 
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Legends 799 
Figure 1. Heat map of the eleven target genes analyzed based on qPCR gene data. 800 
Columns represent mean data values of the five different dietary treatments analyzed in the four 801 
tissues and rows represent single genes. Expression level of each gene was squared-root 802 
normalized in relation to a single sample, so that comparisons could be made in any sense. Means 803 
are depicted by a colour scale, green indicating low (green), neutral (black) or high (red) relative 804 
expression levels, as indicated by the colour bar on the left. fads2d6a, delta-6 fatty acyl desaturase 805 
isoform a; fads2d6b, delta-6 fatty acyl desaturase isoform b; fads26c, delta-6 fatty acyl desaturase 806 
isoform c; fads2d5, delta-5 fatty acyl desaturase; elovl2, fatty acyl elongase 2; elovl5a, fatty acyl 807 
elongase 5 isoform a; elovl5b, fatty acyl elongase isoform b; elovl4, fatty acyl elongase 4; lxr, liver 808 
X receptor; srebp, sterol regulatory element binding protein.  809 
Figure 2. Expression of transcription factors and LC-PUFA biosynthesis pathway genes 810 
in Atlantic salmon liver after nine weeks of feeding. Results are normalized expression ratios 811 
(average +SE, n = 6) of the expression of these genes in fish fed the different diets in relation to 812 
fish fed D5 diet. Diets contain either 5 g kg-1 DHA (D5), 10 g kg-1 DHA (D10) and DHA+EPA 813 
(D5E) or 20 g kg-1 of DHA+ARA (D10A) and DHA+EPA (D10E). fads2d6a, delta-6 fatty acyl 814 
desaturase isoform a; fads2d6b, delta-6 fatty acyl desaturase isoform b; fads26c, delta-6 fatty acyl 815 
desaturase isoform c; fads2d5, delta-5 fatty acyl desaturase; elovl2, fatty acyl elongase 2; elovl5a, 816 
fatty acyl elongase 5 isoform a; elovl5b, fatty acyl elongase isoform b; elovl4, fatty acyl elongase 817 
4; lxr, liver X receptor; srebp, sterol regulatory element binding protein.  818 
Figure 3. Expression, measured by qPCR, of transcription factors and LC-PUFA 819 
biosynthesis pathway genes in Atlantic salmon brain after nine weeks of feeding. Results are 820 
28 
 
normalized expression ratios (average +SE, n = 6) of the expression of these genes in fish fed the 821 
different diets in relation to fish fed D5 diet. Diets contain either 5 g kg-1 DHA (D5), 10 g kg-1 822 
DHA (D10) and DHA+EPA (D5E) or 20 g kg-1 of DHA+ARA (D10A) and DHA+EPA (D10E). 823 
fads2d6a, delta-6 fatty acyl desaturase isoform a; fads2d6b, delta-6 fatty acyl desaturase isoform 824 
b; fads26c, delta-6 fatty acyl desaturase isoform c; fads2d5, delta-5 fatty acyl desaturase; elovl2, 825 
fatty acyl elongase 2; elovl5a, fatty acyl elongase 5 isoform a; elovl5b, fatty acyl elongase isoform 826 
b; elovl4, fatty acyl elongase 4; lxr, liver X receptor; srebp, sterol regulatory element binding 827 
protein. 828 
Figure 4. Expression, measured by qPCR, of transcription factors and LC-PUFA 829 
biosynthesis pathway genes in Atlantic salmon head kidney after nine weeks of feeding. 830 
Results are normalized expression ratios (average +SE, n = 6) of the expression of these genes in 831 
fish fed the different diets in relation to fish fed D5 diet. Diets contain either 5 g kg-1 DHA (D5), 832 
10 g kg-1 DHA (D10) and DHA+EPA (D5E) or 20 g kg-1 of DHA+ARA (D10A) and DHA+EPA 833 
(D10E). fads2d6a, delta-6 fatty acyl desaturase isoform a; fads2d6b, delta-6 fatty acyl desaturase 834 
isoform b; fads26c, delta-6 fatty acyl desaturase isoform c; fads2d5, delta-5 fatty acyl desaturase; 835 
elovl2, fatty acyl elongase 2; elovl5a, fatty acyl elongase 5 isoform a; elovl5b, fatty acyl elongase 836 
isoform b; elovl4, fatty acyl elongase 4; lxr, liver X receptor; srebp, sterol regulatory element 837 
binding protein. 838 
Figure 5. Expression, measured by qPCR, of transcription factors and LC-PUFA 839 
biosynthesis pathway genes in Atlantic salmon gill after nine weeks of feeding. Results are 840 
normalized expression ratios (average +SE, n = 6) of the expression of these genes in fish fed the 841 
different diets in relation to fish fed D5 diet. Diets contain either 5 g kg-1 DHA (D5), 10 g kg-1 842 
DHA (D10) and DHA+EPA (D5E) or 20 g kg-1 of DHA+ARA (D10A) and DHA+EPA (D10E). 843 
fads2d6a, delta-6 fatty acyl desaturase isoform a; fads2d6b, delta-6 fatty acyl desaturase isoform 844 
b; fads26c, delta-6 fatty acyl desaturase isoform c; fads2d5, delta-5 fatty acyl desaturase; elovl2, 845 
29 
 
fatty acyl elongase 2; elovl5a, fatty acyl elongase 5 isoform a; elovl5b, fatty acyl elongase isoform 846 






















Table 1. Formulations of experimental diets (all values are g kg-1). 
 
Ingredient D1 D5 D10 D15 D20 D10A D10E D5E 
Defatted fish meal a 300.0 300.0 300.0 300.0 300.0 300.0 300.0 300.0 
Pregelled starch b 60.0 60.0 60.0 60.0 60.0 60.0 60.0 60.0 
Wheat gluten b  60.0 60.0 60.0 60.0 60.0 60.0 60.0 60.0 
Wheat flour b 155.0 155.0 155.0 155.0 155.0 155.0 155.0 155.0 
Soy protein isolate c 221.0 221.0 221.0 221.0 221.0 221.0 221.0 221.0 
Fish oil a 0.0 0.0 0.0 0.0 0.0 0.0 75.0 30.0 
Olive oil d 92.5 88.3 82.0 77.8 71.5 68.3 55.0 77.5 
DHASCO e 0.0 8.4 21.0 29.4 42.0 21.0 0.0 0.0 
ARASCO e 0.0 0.0 0.0 0.0 0.0 27.5 0.0 0.0 
Butter fat f 92.5 88.3 82.0 77.8 71.5 68.3 55.0 77.5 
L-Histidine g 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
L-Lysine g 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
DL-Methionine g 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 
L-Threonine g 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
Yttrium oxide h 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
CaPO4 g 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 
Vitamins/minerals i 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 
                  
a Fish meal (prior to being defatted): Chilean anchovy meal and oil, Skretting Australia, Cambridge, TAS, 
Australia. b Wheat gluten, wheat flour and pregelatinised starch: Manildra, Auburn, NSW, Australia. c 
Soy protein isolate: ADM, Decatur, IL, USA. d Refined olive oil: Conga Foods, Coburg North, VIC, 
Australia. e DHASCO and ARASCO oils: HuaTai BioPharm Inc, Deyang, Sichuan, China. f Butterfat: 
Woolworths Dairies, Bella Vista, NSW, Australia. g Amino acids and monocalcium phosphate: BEC 
Feed Solutions, Carole Park, QLD, Australia.. h Yttrium oxide: Stanford Materials, Aliso Viejo, 
California, United States. i* Vitamin and mineral premix includes (IU kg-1 or g kg-1 of premix): Vitamin 
A, 2.5MIU; Vitamin D3, 0.25 MIU; Vitamin E, 16.7 g; Vitamin K,3, 1.7 g; Vitamin B1, 2.5 g; Vitamin 
B2, 4.2 g; Vitamin B3, 25 g; Vitamin B5, 8.3; Vitamin B6, 2.0 g; Vitamin B9, 0.8; Vitamin B12, 0.005 g; 
Biotin, 0.17 g; Vitamin C, 75 g; Choline, 166.7 g; Inositol, 58.3 g; Ethoxyquin, 20.8 g; Copper, 2.5 g; 
Ferrous iron, 10.0 g; Magnesium, 16.6 g; Manganese, 15.0 g; Zinc, 25.0 g. 
 
 
Table 2. Nutrient composition of experimental diets (adapted from Glencross et al. 2014). 
 
Ingredient D1 D5 D10 D15 D20 D10A D10E D5E 
         Dry matter (g/kg) 958 967 952 961 943 921 946 944 
Protein (g/kg DM) 525 526 511 513 521 519 517 518 
Fat (g/kg DM) 181 176 204 205 204 178 186 182 
Carbohydrate (g/kg DM) 186 239 230 253 206 214 194 213 
Ash (g/kg DM) 82 72 68 69 71 86 82 74 
Gross energy (kJ/g) 22.3 22.4 23.1 22.7 22.1 22.7 22.5 23.0 
Protein:Energy (g/MJ) 23.5 23.5 22.1 22.6 23.6 22.9 23.0 22.5 
 
 
        All fatty acid data are 
%TFA 
        14:0 6.2 6.0 6.7 6.8 7.4 5.8 7.3 6.8 
16:0 21.5 20.6 21.5 22.9 23.7 20.7 21.9 22.5 
18:0 8.4 7.7 7.3 7.7 7.2 7.4 6.9 7.8 
∑ saturated 36.7 34.4 35.9 37.3 38.7 34.9 36.6 37.4 
16:1n-7 1.4 1.3 1.8 1.9 2.1 1.4 5.1 3.2 
18:1n-9 49.7 48.2 44.3 42.5 39.2 38.8 35.5 43.5 
18:1n-7 4.0 3.9 3.7 3.7 3.7 3.1 3.8 4.0 
∑ monounsaturated 56.0 54.1 51.1 49.1 46.0 44.1 45.8 51.7 
18:2n-6 5.8 6.7 5.9 5.3 4.9 6.5 5.6 6.1 
20:4n-6 0.1 0.1 0.1 0.1 0.1 5.1 0.4 0.1 
22:5n-6 0.0 0.6 1.3 1.5 1.6 1.3 0.0 0.0 
∑ n-6 5.9 7.7 7.7 6.9 6.8 13.8 6.3 6.2 
18:3n-3 0.5 0.8 0.6 0.5 0.5 0.6 0.7 0.6 
20:5n-3 0.4 0.6 0.5 0.4 0.4 0.6 4.8 2.0 
22:5n-3 0.0 0.1 0.2 0.0 0.0 1.9 0.6 0.0 
22:6n-3 0.5 2.0 3.6 5.7 7.6 4.1 3.9 1.7 
∑ n-3 1.4 3.8 5.3 6.6 8.5 7.1 11.3 4.7 
∑ LC-PUFA 1.0 3.4 5.8 7.8 9.8 13.5 10.0 3.8 
n-3/n-6 0.24 0.49 0.69 0.96 1.25 0.52 1.78 0.76 
                  
%TFA = percentage of total fatty acids. LC-PUFA = long chain polyunsaturated fatty acids. 
Table 3. Details of PCR primers used in the present study for real-time quantitative PCR 
(qPCR), The data include sequences and annealing temperatures (Ta) for primer pairs, 












Transcript Primer sequence (5’-3’) Amplicon (bp) Ta (˚C) Accession No. 
Fads2d6a F: CCCCAGACGTTTGTGTCAG 180 56 AY458652a 
R: CCTGGATTGTTGCTTTGGAT 
Fads2d6b F:ATAGAGGGTTTATATAGTAGGGCC 204 58 NM_001172281.1a 
R: GGTGGGACGCTAGAAGTTAA 
Fads2d6c F: CCCACCCCCATCTTAAAACT 171 60 NM_001171780.1a 
R: CTGGGGTCCAAACAAGGTTA 
Fads2d5 F: GTGAATGGGGATCCATAGCA 192 56 AF478472a 
R: AAACGAACGGACAACCAGA 
Elovl2 F: CGGGTACAAAATGTGCTGGT 145 60 TC91192b 
R: TCTGTTTGCCGATAGCCATT 
Elovl5a F:ACAAGACAGGAATCTCTTTCAGATTAA 137 60 AY170327a 
R:TCTGGGGTTACTGTGCTATAGTGTAC 
Elovl5b F: ACAAAAAGCCATGTTTATCTGAAAGA 141 60 DW546112a 
R: AAGTGGGTCTCTCTGGGGCTGTG 
Elovl4 F: TTGTCAAATTGGTCCTGTGC 191 61 HM208347a 
R: TTAAAAGCCCTTTGGGATGA 
Srebp1 F: GCCATGCGCAGGTTGTTTCTTCA 151 63 TC148424b 
 R: TCTGGCCAGGACGCATCTCACACT    
Srebp2 F: GACAGGCACAACACAAGGTG 215 60 DY733476a 
 R: CAGCAGGGGTAAGGGTAGGT    
Lxr F: GCCGCCGCTATCTGAAATCTG 210 58 FJ470290a 
 R: CAATCCGGCAACCAATCTGTAGG    
Cofilin-2 F: AGCCTATGACCAACCCACTG 224 60 TC63899b 
R: TGTTCACAGCTCGTTTACCG 
elf-1α F: CTGCCCCTCCAGGACGTTTACAA 175 60 AF321836a 
R: CACCGGGCATAGCCGATTCC 
Table 4. Fatty acid compositions (percentage of total fatty acids) of liver and head kidney polar lipids of Atlantic salmon  
























































Data expressed as means ± S.D. (n = 3). Diets D1-D20 represent feeds with increasing levels of DHA as described  
in the Materials and Methods section.  Statistical differences were determined by regression analysis (P<0.05).   
DHA, docosahexaenoic acid; DMA, dimethyl acetal; EPA, eicosapentaenoic acid; LC-PUFA, long-chain  
polyunsaturated fatty acids; PUFA, polyunsaturated fatty acids. 1 Includes trace amounts of 20:3n-9; 2 Totals include 
 18:3n-6; 3 Totals include 18:4n-3, 20:3n-3 and 20:4n-3; 4 Totals include 20:3n-3 and 20:4n-3. 
 
Fatty acid D1 D5 D10 D15 D20 R2 P-value 
Liver        
Lipids % (wet wt.) 4.9 ± 1.2 4.9 ± 1.2 5.1 ± 0.9 5.1 ± 0.4 5.0 ± 0.5 0.001 0.761 
∑ saturated 26.8 ± 0.8 28.7 ± 0.9 28.2 ± 0.8 28.1 ± 0.4 26.7 ± 0.2 0.019 0.625 
∑ MUFA 28.7 ± 0.9 24.5 ± 1.9 23.2 ± 1.5 22.7 ± 1.3 20.5 ± 0.5 0.780 0.000 
18:2n-6 3.8 ± 0.2 3.6 ± 0.2 3.2 ± 0.6 3.0 ± 0.2 2.7 ± 0.1 0.728 0.000 
20:2n-61 1.4 ± 0.1 1.1 ± 0.2 1.0 ± 0.0 0.9 ± 0.2 0.8 ± 0.0 0.708 0.000 
20:3n-6 4.5 ± 0.6 3.1 ± 0.9 2.3 ± 0.6 1.5 ± 0.4 1.1 ± 0.1 0.869 0.000 
20:4n-6 5.2 ± 0.7 4.1 ± 0.4 4.0 ± 0.3 4.2 ± 0.6 4.8 ± 0.4 0.037 0.495 
22:4n-6 0.4 ± 0.0 0.3 ± 0.1 0.2 ± 0.0 0.2 ± 0.1 0.3 ± 0.0 0.179 0.116 
22:5n-6 1.1 ± 0.2 3.7 ± 0.6 5.1 ± 1.8 6.7 ± 1.1 7.9 ± 0.4 0.848 0.000 
∑ n-6 PUFA2 16.6 ± 0.3 16.0 ± 1.9 15.9 ± 1.9 16.6 ± 1.7 17.5 ± 0.5 0.057 0.393 
18:3n-3 0.1 ± 0.0 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.0 0.1 ± 0.0 0.061 0.374 
20:5n-3 3.1 ± 0.1 3.0 ± 1.5 3.1 ± 1.4 2.2 ± 0.9 1.7 ± 0.2 0.304 0.033 
22:5n-3 1.5 ± 0.2 1.0 ± 0.4 0.9 ± 0.4 0.7 ± 0.3 0.5 ± 0.0 0.601 0.001 
22:6n-3 22.3 ± 0.7 26.2 ± 2.7 28.0 ± 2.6 29.4 ± 1.3 32.7 ± 0.5 0.816 0.000 
∑ n-3 PUFA3 27.3 ± 0.6 30.4 ± 4.7 32.4 ± 4.1 32.6 ± 2.5 35.2 ± 0.7 0.502 0.003 
DMA n.d. n.d. n.d. n.d. n.d. - - 
∑ n-3 LC-PUFA4 27.0 ± 0.6 30.3 ± 4.6 32.2 ± 4.0 32.4 ± 2.5 35.0 ± 0.6 0.514 0.003 
EPA/ARA 0.6 ± 0.1 0.7 ± 0.4 0.8 ± 0.4 0.5 ± 0.2 0.4 ± 0.1 0.164 0.135 
        
Head kidney        
Lipids % (wet wt.) 5.3 ± 2.8 4.3 ± 1.2 3.7 ± 0.9 3.8 ± 0.7 3.4 ± 1.1 0.182 0.105 
∑ saturated 30.4 ± 0.2 29.8 ± 0.6 30.5 ± 0.3 30.8 ± 0.7 30.6 ± 0.6 0.123 0.199 
∑ MUFA 26.5 ± 0.5 24.8 ± 0.6 24.7 ± 0.8 22.4 ± 0.4 21.0 ± 1.1 0.868 0.000 
18:2n-6 3.6 ± 0.2 3.2 ± 0.2 2.9 ± 0.1 2.5 ± 0.1 2.4 ± 0.0 0.883 0.000 
20:2n-61 1.0 ± 0.0 0.8 ± 0.1 0.7 ± 0.0 0.6 ± 0.0 0.5 ± 0.0 0.935 0.000 
20:3n-6 2.7 ± 0.2 2.0 ± 0.3 1.2 ± 0.1 0.8 ± 0.1 0.7 ± 0.0 0.940 0.000 
20:4n-6 5.3 ± 0.1 4.2 ± 0.4 4.4 ± 0.1 5.0 ± 0.3 5.1 ± 0.7 0.009 0.741 
22:4n-6 0.2 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.576 0.001 
22:5n-6 0.9 ± 0.1 3.3 ± 0.3 5.4 ± 0.1 6.1 ± 0.1 7.2 ± 0.1 0.885 0.000 
∑ n-6 PUFA2 13.8 ± 0.5 13.6 ± 0.5 14.7 ± 0.0 15.1 ± 0.3 16.0 ± 0.6 0.774 0.000 
18:3n-3 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.049 0.427 
20:5n-3 3.6 ± 0.2 3.5 ± 0.5 2.2 ± 0.3 2.4 ± 0.3 2.1 ± 0.4 0.641 0.000 
22:5n-3 0.9 ± 0.0 0.7 ± 0.1 0.5 ± 0.0 0.4 ± 0.0 0.4 ± 0.0 0.879 0.000 
22:6n-3 21.5 ± 0.5 24.4 ± 0.6 24.5 ± 0.5 25.8 ± 0.8 27.1 ± 1.0 0.830 0.000 
∑ n-3 PUFA3 26.4 ± 0.7 29.1 ± 1.0 27.4 ± 0.7 29.0 ± 1.1 29.9 ± 1.3 0.429 0.008 
DMA 2.7 ± 0.1 2.5 ± 0.4 2.5 ± 0.1 2.6 ± 0.4 2.5 ± 0.3 0.024 0.578 
∑ n-3 LC-PUFA4 26.1 ± 0.7 28.9 ± 1.0 27.2 ± 0.6 28.8 ± 1.1 29.7 ± 1.3 0.444 0.007 
EPA/ARA 0.7 ± 0.0 0.8 ± 0.1 0.5 ± 0.1 0.5 ± 0.0 0.4 ± 0.0 0.633 0.000 
Table 5. Fatty acid compositions (percentage of total fatty acids) of liver and head kidney polar lipids of Atlantic  
































Data expressed as means ± S.D. (n = 3). Diets represent feeds containing 10 g kg-1 DHA (D10) or DHA+EPA (D5E), and feeds  
containing 20 g kg-1 DHA (D20), DHA+ARA (D10A) or DHA+EPA (D10E). Asterisks denote statistical differences between  
the 10 g kg-1 diets as determined by one-way ANOVA (P<0.05).  Different superscript letters within a row represent significant  
differences between the 20 g kg-1 diets as determined by one-way ANOVA with Tukey’s comparison test (P<0.05)DHA,  
docosahexaenoic acid; DMA, dimethyl acetal; EPA, eicosapentaenoic acid; LC-PUFA, long-chain polyunsaturated fatty acids; 
PUFA, polyunsaturated fatty acids. 1 Includes trace amounts of 20:3n-9; 2 Totals include 18:3n-6; 3 Totals include 18:4n-3, 20:3n-3  
and 20:4n-3; 4 Totals include 20:3n-3 and 20:4n-3. 
 
 10 g kg-1 diets 
 
20 g kg-1 diets 
Fatty acid D10 D5E 
 
D20 D10A D10E 
Liver       
Lipids % (wet wt.) 5.1 ± 0.9 4.9 ± 0.8  5.0 ± 0.5 4.4 ± 1.0 4.1 ± 0.0 
∑ saturated 28.2 ± 0.8 26.7 ± 1.6 
 
26.7 ± 0.2 27.9 ± 1.4 28.0 ± 1.1 
∑MUFA 23.2 ± 1.5 25.7 ± 0.7 
 
20.5 ± 0.5 20.1 ± 0.9 21.3 ± 1.4 
18:2n-6 3.2 ± 0.6 3.2 ± 0.1 
 
2.7 ± 0.1 1.9 ± 0.6 2.4 ± 0.1 
20:2n-61 1.0 ± 0.0 1.1 ± 0.1 
 
0.8 ± 0.0a 0.6 ± 0.1b 0.7 ± 0.1ab 
20:3n-6 2.3 ± 0.6 2.8 ± 0.7 
 
1.1 ± 0.1 1.4 ± 0.1 1.3 ± 0.3 
20:4n-6 4.0 ± 0.3 3.3 ± 0.6 
 
4.8 ± 0.4b 13.8 ± 0.6a 2.9 ± 0.1c 
22:4n-6 0.2 ± 0.0 0.2 ± 0.0 
 
0.3 ± 0.0b 1.5 ± 0.2a 0.1 ± 0.0c 
22:5n-6 5.1 ± 1.8 0.6 ± 0.0* 
 
7.9 ± 0.4a 6.9 ± 0.7a 0.5 ± 0.1b 
∑ n-6 PUFA2 15.9 ± 1.9 11.2±0.3* 
 
17.5 ± 0.5b 26.1 ± 1.0a 8.0 ± 0.3c 
18:3n-3 0.1 ± 0.1 0.1 ± 0.1 
 
0.1 ± 0.0 0.1 ± 0.1 0.1 ± 0.0 
20:5n-3 3.1 ± 1.4 4.7 ± 0.6 
 
1.7 ± 0.2b 1.1 ± 0.2b 6.6 ± 0.8a 
22:5n-3 0.9 ± 0.4 1.5 ± 0.1 
 
0.5 ± 0.0b 0.7 ± 0.1b 2.1 ± 0.2a 
22:6n-3 28.0 ± 2.6 29.6 ± 2.0 
 
32.7 ± 0.5a 23.9 ± 0.9b 33.4 ±0.4a 
∑ n-3 PUFA3 32.4 ± 4.1 36.2 ± 2.6 
 
35.2 ± 0.7b 25.8 ± 0.9c 42.6 ±1.0a 
∑ DMA n.d. n.d.  n.d. n.d. n.d. 
∑ n-3 LC-PUFA4 32.2 ± 4.0 36.0 ± 2.5 
 
35.0 ± 0.6b 25.7 ± 0.9c 42.3 ±1.0a 
EPA/ARA 0.8 ± 0.4 1.5 ± 0.1 
 
0.4 ± 0.1b 0.1 ± 0.0c 2.3 ± 0.2a 
       
Head kidney       
Lipids % (wet wt.) 3.7 ± 0.9 4.2 ± 0.7  3.4 ± 1.1 3.7 ± 0.1 5.1 ± 0.2 
∑ saturated 30.5 ± 0.3 31.5±0.2*  30.6 ± 0.6 31.5 ± 1.3 32.3 ± 0.5 
∑MUFA 24.7 ± 0.8 25.6 ± 0.5  21.0 ± 1.1 22.1 ± 0.9 22.4 ± 1.3 
18:2n-6 2.9 ± 0.1 2.8 ± 0.2  2.4 ± 0.0a 2.3 ± 0.0b 2.2 ± 0.0c 
20:2n-61 0.7 ± 0.0 0.6 ± 0.0*  0.5 ± 0.0a 0.3 ± 0.0b 0.4 ± 0.0b 
20:3n-6 1.2 ± 0.1 1.6 ± 0.1*  0.7 ± 0.0 0.9 ± 0.1 0.7 ± 0.1 
20:4n-6 4.4 ± 0.1 3.4 ± 0.3*  5.1 ± 0.7b 14.6 ± 0.5a 3.7 ± 0.3c 
22:4n-6 0.1 ± 0.0 0.1 ± 0.0*  0.1 ± 0.0b 0.8 ± 0.1a 0.1 ± 0.0b 
22:5n-6 5.4 ± 0.1 0.4 ± 0.0*  7.2 ± 0.1a 4.0 ± 0.3b 0.4 ± 0.0c 
∑ n-6 PUFA2 14.7 ± 0.0 8.9 ± 0.1*  16.0 ± 0.6b 22.9 ± 1.1a 7.5 ± 0.1c 
18:3n-3 0.1 ± 0.0 0.1 ± 0.0  0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 
20:5n-3 2.2 ± 0.3 5.3 ± 0.5*  2.1 ± 0.4b 1.1 ± 0.2b 6.9 ± 1.8a 
22:5n-3 0.5 ± 0.0 1.3 ± 0.2*  0.4 ± 0.0b 0.5 ± 0.0b 1.5 ± 0.1a 
22:6n-3 24.5 ± 0.5 24.0 ± 0.7  27.1 ± 1.0a 19.1 ± 1.0b 26.3 ±0.6a 
∑ n-3 PUFA3 27.4 ± 0.7 31.1±0.4*  29.9 ± 1.3b 20.9 ± 1.2c 35.1 ±2.1a 
∑ DMA 2.5 ± 0.1 2.7 ± 0.1  2.5 ± 0.3 2.7 ± 0.1 2.6 ± 0.4 
∑ n-3 LC-PUFA4 27.2 ± 0.6 30.9±0.5*  29.7 ± 1.3b 20.7 ± 1.2c 35.0 ±2.1a 
EPA/ARA 0.5 ± 0.1 1.6 ± 0.1*  0.4 ± 0.0b 0.1 ± 0.0c 1.8 ± 0.3a 
Table 6. Fatty acid compositions (percentage of total fatty acids) of head kidney polar lipids of Atlantic 




























Data expressed as means ± S.D. (n = 3). Diets D1-D20 represent feeds with increasing levels of DHA as described in  
the Materials and Methods section. Statistical differences were determined by regression analysis (P < 0.05). DHA,  
docosahexaenoic acid; DMA, dimethyl acetal; EPA, eicosapentaenoic acid; LC-PUFA, long-chain polyunsaturated  
fatty acids; PUFA, polyunsaturated fatty acids.1 Includes trace amounts of 20:3n-9; 2 Totals include 18:3n-6; 3 Totals  
include 18:4n-3, 20:3n-3 and 20:4n-3; 4 Totals include 20:3n-3 and 20:4n-3. 
 
Fatty acid D1 D5 D10 D15 D20 R2 P-value 
Brain        
Lipids % (wet wt.) 7.5 ± 0.4 7.6 ± 0.7 7.4 ± 0.7 7.4 ± 0.3 7.0 ± 0.2 0.15 0.149 
∑ saturated 23.6 ± 0.6 24.5 ± 0.6 24.1 ± 0.6 24.9 ± 0.4 25.0 ± 0.4 0.457 0.006 
∑ MUFA 40.8 ± 0.8 39.1 ± 0.9 40.1 ± 1.5 38.8 ± 0.7 38.5 ± 1.1 0.329 0.025 
18:2n-6 0.3 ± 0.0 0.3 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.737 0.000 
20:2n-61 n.d. n.d. n.d. n.d. n.d. - - 
20:3n-6 n.d. n.d. n.d. n.d. n.d. - - 
20:4n-6 1.3 ± 0.1 1.3 ± 0.0 1.3 ± 0.1 1.4 ± 0.0 1.4 ± 0.0 0.494 0.003 
22:4n-6 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.054 0.405 
22:5n-6 0.1 ± 0.0 0.5 ± 0.0 0.7 ± 0.0 0.8 ± 0.0 0.8 ± 0.0 0.836 0.000 
∑ n-6 PUFA2 2.3 ± 0.1 2.5 ± 0.1 2.6 ± 0.1 2.8 ± 0.1 2.8 ± 0.1 0.782 0.000 
18:3n-3 n.d. n.d. n.d. n.d. n.d. - - 
20:5n-3 4.4 ± 0.1 4.2 ± 0.1 4.1 ± 0.1 4.0 ± 0.0 4.0 ± 0.0 0.839 0.000 
22:5n-3 1.8 ± 0.2 1.7 ± 0.1 1.6 ± 0.1 1.6 ± 0.0 1.6 ± 0.0 0.412 0.010 
22:6n-3 19.0 ± 0.6 20.3 ± 0.6 19.7 ± 1.0 20.3 ± 0.7 20.7 ± 0.7 0.304 0.033 
∑ n-3 PUFA3 25.3 ± 0.5 26.4 ± 0.6 25.6 ± 1.0 26.1 ± 0.6 26.4 ± 0.8 0.127 0.192 
DMA 7.8 ± 0.3 7.4 ± 0.3 7.4 ± 0.2 7.3 ± 0.3 7.2 ± 0.2 0.411 0.010 
∑ n-3 LC-PUFA4 25.3 ± 0.5 26.4 ± 0.6 25.6 ± 1.0 26.1 ± 0.6 26.4 ± 0.8 0.127 0.192 
EPA/ARA 3.4 ± 0.2 3.3 ± 0.1 3.1 ± 0.2 2.9 ± 0.1 2.8 ± 0.0 0.736 0.000 
        
Gill        
Lipids % (wet wt.) 1.6 ± 0.4 2.2 ± 0.5 1.5 ± 0.1 1.6 ± 0.3 1.8 ± 0.5 0.001 0.787 
∑ saturated 31.6 ± 0.3 31.6 ± 0.2 32.6 ± 2.1 33.4 ± 0.6 32.4 ± 0.2 0.195 0.100 
∑ MUFA 29.0 ± 0.6 28.2 ± 1.3 28.7 ± 1.4 27.2 ± 1.3 25.7 ± 0.4 0.535 0.002 
18:2n-6 3.0 ± 0.1 2.5 ± 0.3 2.3 ± 0.1 2.1 ± 0.2 2.0 ± 0.1 0.818 0.000 
20:2n-61 0.8 ± 0.1 0.6 ± 0.1 0.6 ± 0.0 0.5 ± 0.0 0.5 ± 0.0 0.789 0.000 
20:3n-6 2.2 ± 0.1 1.5 ± 0.2 1.0 ± 0.0 0.6 ± 0.1 0.6 ± 0.0 0.934 0.000 
20:4n-6 5.8 ± 0.6 4.6 ± 0.1 4.9 ± 0.3 5.0 ± 0.2 5.2 ± 0.2 0.034 0.509 
22:4n-6 0.4 ± 0.1 0.2 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.043 0.458 
22:5n-6 0.9 ± 0.1 3.1 ± 0.3 4.7 ± 0.5 5.3 ± 0.2 6.2 ± 0.2 0.863 0.000 
∑ n-6 PUFA2 13.1 ± 0.8 12.7 ± 0.7 13.8 ± 0.8 13.9 ± 0.5 14.7 ± 0.2 0.530 0.002 
18:3n-3 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.001 0.907 
20:5n-3 2.3 ± 0.3 2.0 ± 0.2 1.6 ± 0.3 1.6 ± 0.2 1.7 ± 0.1 0.521 0.002 
22:5n-3 0.7 ± 0.0 0.5 ± 0.0 0.4 ± 0.1 0.4 ± 0.0 0.4 ± 0.0 0.797 0.000 
22:6n-3 18.8 ± 0.3 20.6 ± 1.3 19.0 ± 2.2 19.9 ± 0.8 21.8 ± 0.5 0.251 0.057 
∑ n-3 PUFA3 22.1 ± 0.5 23.4 ± 1.3 21.2 ± 2.6 22.0 ± 0.6 23.9 ± 0.4 0.047 0.440 
DMA 4.0 ± 0.2 4.1 ± 0.3 3.6 ± 0.1 3.4 ± 0.2 3.2 ± 0.1 0.711 0.000 
∑ n-3 LC-PUFA4 21.9 ± 0.5 23.2 ± 1.3 21.0 ± 2.5 21.9 ± 0.6 23.8 ± 0.4 0.054 0.403 
EPA/ARA 0.4 ± 0.1 0.4 ± 0.1 0.3 ± 0.1 0.3 ± 0.0 0.3 ± 0.0 0.438 0.007 
Table 7. Fatty acid compositions (percentage of total fatty acids) of brain and gill polar lipids of Atlantic salmon  






























Data expressed as means ± S.D. (n = 3). Diets represent feeds containing 10 g kg-1 DHA (D10) or DHA+EPA (D5E),  
and feeds containing 20 g kg-1 DHA (D20), DHA+ARA (D10A) or DHA+EPA (D10E). Asterisks denote statistical  
differences between the 10 g kg-1 diets as determined by one-way ANOVA (P<0.05).  Different superscript letters  
within a row represent significant differences between the 20 g kg-1 diets as determined by one-way ANOVA with  
Tukey’s comparison test (P<0.05). DHA, docosahexaenoic acid; DMA, dimethyl acetal; EPA, eicosapentaenoic acid;  
LC-PUFA, long-chain polyunsaturated fatty acids; PUFA, polyunsaturated fatty acids.1 Includes trace amounts of  
20:3n-9; 2 Totals include 18:3n-6; 3 Totals include 18:4n-3, 20:3n-3 and 20:4n-3; 4 Totals include 20:3n-3 and 20:4n-3. 
 10 g kg-1 diets 
 
20 g kg-1 diets 
Fatty acid D10 D5E 
 
D20 D10A D10E 
Brain       
Lipids % (wet wt.) 7.4 ± 0.7b 8.3 ± 0.6a  7.0 ± 0.2 7.8 ± 0.2 8.5 ± 1.5 
∑ saturated 24.1 ± 0.6 23.9 ± 0.8  25.0 ± 0.4a 23.9 ± 0.1b 24.9 ± 0.2a 
∑MUFA 40.1 ± 1.5 40.5 ± 1.4  38.5 ± 1.1 40.2 ± 0.5 39 ± 0.7 
18:2n-6 0.2 ± 0.0 0.5 ± 0.4  0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 
20:2n-61 n.d. n.d.  n.d. n.d. n.d. 
20:3n-6 n.d. n.d.  n.d. n.d. n.d. 
20:4n-6 1.3 ± 0.1 1.0 ± 0.1*  1.4 ± 0.0b 2.6 ± 0.2a 1.0 ± 0.0c 
22:4n-6 0.1 ± 0.0 0.1 ± 0.0*  0.1 ± 0.0b 0.2 ± 0.0a 0.1 ± 0.0c 
22:5n-6 0.7 ± 0.0 0.1 ± 0.0*  0.8 ± 0.0a 0.6 ± 0.0a 0.0 ± 0.0b 
∑ n-6 PUFA2 2.6 ± 0.1 2.0 ± 0.3*  2.8 ± 0.1b 3.8 ± 0.2a 1.5 ± 0.1c 
18:3n-3 n.d. n.d.  n.d. n.d. n.d. 
20:5n-3 4.1 ± 0.1 4.6 ± 0.2*  4.0 ± 0.0b 3.8 ± 0.0c 4.8 ± 0.1a 
22:5n-3 1.6 ± 0.1 1.9 ± 0.0*  1.6 ± 0.0b 1.5 ± 0.0b 2.0 ± 0.1a 
22:6n-3 19.7 ± 1.0 18.9 ± 1.2  20.7 ± 0.7a 18.7 ± 0.2b 20.0 ± 0.3a 
∑ n-3 PUFA3 25.6 ± 1.0 25.7 ± 1.3  26.4 ± 0.8a 24.2 ± 0.1b 27.0 ± 0.6a 
∑ DMA 7.4 ± 0.2 7.9 ± 0.8  7.2 ± 0.2b 7.8 ± 0.1a 7.5 ± 0.2ab 
∑ n-3 LC-PUFA4 25.6 ± 1.0 25.7 ± 1.3  26.4 ± 0.8a 24.2 ± 0.1b 27.0 ± 0.6a 
EPA/ARA 3.1 ± 0.2 4.6 ± 0.2*  2.8 ± 0.0b 1.5 ± 0.1c 5.0 ± 0.1a 
       
Gill       
Lipids % (wet wt.) 1.5 ± 0.1 1.5 ± 0.0  1.8 ± 0.5 1.5 ± 0.1 1.6 ± 0.1 
∑ saturated 32.6 ± 2.1 31.8 ± 0.9  32.4 ± 0.2 32.8 ± 1.1 34.0 ± 1.7 
∑MUFA 28.7 ± 1.4 28.9 ± 0.8  25.7 ± 0.4 25.2 ± 0.3 26.9 ± 1.4 
18:2n-6 2.3 ± 0.1 2.5 ± 0.1*  2.0 ± 0.1a 1.7 ± 0.1b 1.9 ± 0.1ab 
20:2n-61 0.6 ± 0.0 0.6 ± 0.0  0.5 ± 0.0a 0.4 ± 0.0b 0.4 ± 0.0b 
20:3n-6 1.0 ± 0.0 1.4 ± 0.1*  0.6 ± 0.0 0.6 ± 0.1 0.7 ± 0.1 
20:4n-6 4.9 ± 0.3 4.2 ± 0.1*  5.2 ± 0.2b 11.6 ± 1.0a 4.1 ± 0.3c 
22:4n-6 0.3 ± 0.0 0.2 ± 0.0  0.3 ± 0.0b 1.5 ± 0.2a 0.3 ± 0.0b 
22:5n-6 4.7 ± 0.5 0.5 ± 0.0*  6.2 ± 0.2a 3.8 ± 0.1b 0.5 ± 0.0c 
∑ n-6 PUFA2 13.8 ± 0.8 9.5 ± 0.1*  14.7 ± 0.2b 19.6 ± 1.4a 7.8 ± 0.3c 
18:3n-3 0.1 ± 0.0 0.1 ± 0.0  0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 
20:5n-3 1.6 ± 0.3 4.0 ± 0.6*  1.7 ± 0.1b 1.0 ± 0.0c 4.7 ± 0.2a 
22:5n-3 0.4 ± 0.1 1.1 ± 0.2*  0.4 ± 0.0b 0.4 ± 0.0b 1.2 ± 0.1a 
22:6n-3 19.0 ± 2.2 20.9 ± 1.1  21.8 ± 0.5a 17.1 ± 0.5b 21.7 ± 2.6a 
∑ n-3 PUFA3 21.2 ± 2.6 26.2 ± 0.4*  23.9 ± 0.4a 18.6 ± 0.5b 27.9 ± 2.7a 
∑ DMA 3.6 ± 0.1 3.5 ± 0.3  3.2 ± 0.1b 3.8 ± 0.1a 3.4 ± 0.1b 
∑ n-3 LC-PUFA4 21.0 ± 2.5 26.0 ± 0.4*  23.8 ± 0.4a 18.4 ± 0.5b 27.7 ± 2.7a 
EPA/ARA 0.3 ± 0.1 0.9 ± 0.1*  0.3 ± 0.0b 0.1 ± 0.0c 1.1 ± 0.1a 
